A consensus paper published in 2025 provides pragmatic advice on the diagnosis and treatment of subsyndromal anxiety disorder (SSA). If it has been established that the patient has SSA, it is recommended that non-drug treatment measures be initiated first. If this does not lead to the desired success, drug therapy should be considered. Phytotherapeutic treatment with a standardized lavender oil extract has been shown to be effective and safe in studies of SSA.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- B-cell lymphomas
Bispecific antibodies – mechanisms, evidence and future role
- Dermatoscopic findings of granulomatous diseases
Cutaneous sarcoidosis, necrobiosis lipoidica and granuloma anulare
- Clostridioides difficile infection: specific therapy
Importance of vancomycin and fidaxomicin has increased
- Study report
Asthma exacerbation risk in patients with a psychological comorbidity
- Neuropathies - CIDP
Differentiate chronic inflammatory demyelinating polyneuropathy (CIDP)
- Treatment of type 2 diabetes: paradigm shift continues
Cardiorenal organ protection is increasingly coming to the fore
- Semaglutide and tirzepatide in HFpEF and T2D/obesity
Prospect of improved cardiovascular prognosis
- Case report: alveolar sarcoidosis